Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
cholangiocarcinoma/tyrosine
Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 139 rezultatus
High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
The incidence, prevalence, and mortality of intrahepatic cholangiocarcinoma (ICC) are increasing worldwide. Protein tyrosine kinase-7 (PTK7) is upregulated in many common human cancers. However, its expression in ICC has not been studied. The present study aimed to explore the underlying
The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Pro-tumorigenic function of the p38 kinase plays a critical role in human cholangiocarcinogenesis. However, the underlying mechanism remains incompletely understood. Here, we report that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), contributes to the pro-tumorigenic
Expression of Etk/Bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Epithelial and endothelial tyrosine kinase (Etk), also known as bone marrow X kinase (Bmx) plays an important role in the growth, differentiation, apoptosis, proliferation, and tumorigenicity of epithelial cells. The purpose of this study was to investigate the expression of Etk/Bmx in
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy.
METHODS
We profiled the transcriptomes from 104 surgically resected
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Aberrant expression and signaling of epidermal growth factor receptor (ErbB) family receptor tyrosine kinases, most notably that of ErbB2 and ErbB1, have been implicated in the molecular pathogenesis of intrahepatic cholangiocarcinoma. Constitutive overexpression of ErbB2 and/or ErbB1 in malignant
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
UNASSIGNED
Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently under
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Cholangiocarcinoma, also known as bile duct cancer, is the second most common primary hepatic carcinoma with a median survival of less than 2 years. The molecular mechanisms underlying the development of this disease are not clear. To survey activated tyrosine kinases signaling in
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The protein tyrosine phosphatase PTP4A1 is a key molecule that activates tyrosine phosphorylation, which is important for cancer progression and metastasis. However, the clinical implications and biological function of PTP4A1 in intrahepatic cholangiocarcinoma (ICC) remains unknown. Here, we showed
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Cholangiocarcinoma is an aggressive malignancy with limited therapeutic options. MEK inhibition and antiangiogenic therapies have individually shown modest activity in advanced cholangiocarcinoma, whereas dual inhibition of these pathways has not been previously evaluated. We evaluated the safety
YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The Hippo pathway effector, Yes-associated protein (YAP), is a transcriptional coactivator implicated in cholangiocarcinoma (CCA) pathogenesis. YAP is known to be regulated by a serine/threonine kinase relay module (MST1/2-LATS1/2) culminating in phosphorylation of YAP at Serine 127 and cytoplasmic
The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Although the survival of patients with cholangiocarcinoma has improved, the prognosis remains unfavorable. The overexpression of mesenchymal-epithelial transition factor (MET) and recepteur d'origine nantais (RON) has been considered to be indicative of a poor prognosis in some types of cancer. On
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutics targets for tyrosine kinase inhibitors.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Cholangiocarcinoma (CCA) is a refractory cancer with limited treatment options and poorly understood molecular mechanisms underlying tumor development. The most effective treatment is surgical resection; however, patients are highly prone to recurrence. Moreover, considering that most patients are
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
